Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
2 AI Healthcare Stocks to Buy Right Now
06:45am, Tuesday, 31'st Mar 2026
AI-powered drug discovery and development is now a possibility. Artificial intelligence is also able to help caregivers navigate a complex collection of ever-changing treatment options.
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
06:51pm, Friday, 27'th Mar 2026
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.94, representing a -6.67% change from its previous close.
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?
12:31pm, Friday, 27'th Mar 2026
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
07:59am, Wednesday, 25'th Mar 2026
Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodma
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.
06:25am, Saturday, 21'st Mar 2026
Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
08:02pm, Friday, 20'th Mar 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors
06:50pm, Thursday, 19'th Mar 2026
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.37, indicating a +1.51% shift from the previous trading day.
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:45pm, Tuesday, 10'th Mar 2026
Recursion Pharmaceuticals (RXRX) reached $3.44 at the closing of the latest trading day, reflecting a -1.99% change compared to its last close.
Can This AI Stock Bounce Back in 2026?
11:55am, Sunday, 08'th Mar 2026
Recursion Pharmaceuticals is looking to use AI to speed up R&D in the biotech industry. The company has yet to show the value of its approach and faces significant uncertainty.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
12:35pm, Friday, 06'th Mar 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
DNB Asset Management AS Purchases New Position in Recursion Pharmaceuticals, Inc. $RXRX
04:18am, Wednesday, 04'th Mar 2026
DNB Asset Management AS purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institution
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
01:20pm, Wednesday, 25'th Feb 2026
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago.
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
12:47pm, Wednesday, 25'th Feb 2026
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
11:26am, Wednesday, 25'th Feb 2026
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
06:30am, Wednesday, 25'th Feb 2026
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and fin
